Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

被引：4
|
作者：
Trigo, J. [1 ]
Cho, B. C. [2 ]
Park, K. [3 ]
Girard, N. [4 ]
Viteri, S. [5 ]
Garrido, P. [6 ]
Krebs, M. G. [7 ,8 ]
Thayu, M. [9 ]
Knoblauch, R. E. [9 ]
Xie, J. [9 ]
Bauml, J. M. [9 ]
Schnepp, R. W. [9 ]
Londhe, A. [9 ]
Mahadevia, P. [9 ]
Leighl, N. [10 ]
机构：
[1] Hosp Univ Virgen Victoria & Reg, IBIMA, Malaga, Spain
[2] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Inst Curie, Thorax Inst, Paris, France
[5] UOMI Canc Ctr, Clin Mi Tres Torres, Barcelona, Spain
[6] Hosp Univ Ramon & Cajal, IRYCIS, Madrid, Spain
[7] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Manchester, Lancs, England
[8] Christie NHS Fdn Trust, Manchester Acad, Hlth Sci Ctr, Manchester, Lancs, England
[9] Janssen R&D, Spring House, PA USA
[10] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20P
引用
收藏
页码：S38 / S39
页数：2
相关论文
共 50 条
  • [31] Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    O'Leary, Connor
    Gasper, Harry
    Sahin, Katherine B.
    Tang, Ming
    Kulasinghe, Arutha
    Adams, Mark N.
    Richard, Derek J.
    O'Byrne, Ken J.
    PHARMACEUTICALS, 2020, 13 (10) : 1 - 16
  • [32] Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
    Passaro, A.
    Yu, H. A.
    Nguyen, D.
    Lee, V. H. F.
    Soo, R. A.
    Kim, S. H.
    Daga, H.
    Tan, D. S. W.
    Kim, S-W.
    Juan Vidal, O. J.
    Piotrowska, Z.
    Keeton, E. K.
    Liu, T.
    Li, S.
    Jones, J.
    Ruiter, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S803 - S804
  • [33] Amivantamab vs real-world (RW) therapies for advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (E20i) in Japan
    Okahisa, M.
    Udagawa, H.
    Matsumoto, S.
    Kato, T.
    Yokouchi, H.
    Furuya, N.
    Kanemaru, R.
    Toyozawa, R.
    Nishiyama, A.
    Ohashi, K.
    Miyamoto, S.
    Nishino, K.
    Oi, H.
    Low, G. K. M.
    Zhuo, J.
    Yu, D. Young
    Yang, Y.
    Lim, C.
    Kleinman, N. J.
    Goto, K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1061 - S1061
  • [34] FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    Chon, Katie
    Larkins, Erin
    Chatterjee, Somak
    Mishra-Kalyani, Pallavi S.
    Aungst, Stephanie
    Wearne, Emily
    Subramaniam, Sriram
    Li, Yangbing
    Liu, Jiang
    Sun, Jielin
    Charlab, Rosane
    Zhao, Hong
    Saritas-Yildirim, Banu
    Bikkavilli, Rama Kamesh
    Ghosh, Soma
    Philip, Reena
    Beaver, Julia A.
    Singh, Harpreet
    CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3262 - 3266
  • [35] Amivantamab compared with European, real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), after failure of platinum-based therapy
    Girard, N.
    Popat, S.
    Rahhali, N.
    Rodrigues, B.
    Schioppa, C. A.
    Pick-Lauer, C.
    Adamczyk, A.
    Sermon, J.
    Diels, J.
    Penton, J.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1062 - S1062
  • [36] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Simon Vyse
    Paul H. Huang
    Signal Transduction and Targeted Therapy, 4
  • [37] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Vyse, Simon
    Huang, Paul H.
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
  • [38] MATCHING-ADJUSTED INDIRECT COMPARISON OF AMIVANTAMAB VS. MOBOCERTINIB IN EGFR EXON 20 INSERTION-MUTATED NON-SMALL CELL LUNG CANCER
    Van Sanden, S.
    Rahhali, N.
    Schioppa, C.
    Diels, J.
    Rodrigues, B.
    Chandler, C.
    Kapetanakis, V
    Jain, R.
    Li, T.
    VALUE IN HEALTH, 2022, 25 (07) : S526 - S526
  • [39] Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab
    Jatkoe, Timothy
    Wang, Songbai
    Odegaard, Justin I.
    Roth, Anne Marie Velasco
    Osgood, Drew
    Martinez, Gabriela
    Lucas, Paul
    Curtin, Joshua C.
    Karkera, Jayaprakash
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (11): : 1181 - 1188
  • [40] Bispecific Approach for Patients with non-small cell Lung Cancer Benefiting from Amivantamab for EGFR-Exon-20-Insertion Mutations
    Rudesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 214 - 214
12345